Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Mouse IgG1 Monoclonal Antibody.
Clone: 1116-NS-19-9.
Isotype: Mouse IgG1 Kappa.
Source:The anti-human CA19-9 monoclonal antibody (clone: 1116-NS-19-9) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 1116-NS-19-9) specifically binds to human CA19-9.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CA19-9 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CA19-9 monoclonal antibody of clone 1116-NS-19-9 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Differential expression of CD175 and CA19-9 in pancreatic adenocarcinoma
Kozak, R. P., et al. Sci Rep. 2024 Feb 3;14(1):2698. doi: 10.1038/s41598-024-52698-8. PMID: 38307988
The 1116-NS-19-9 antibody detected CA19-9 in pancreatic ductal adenocarcinoma (PDAC) samples via semi-quantitative IHC, showing heterogeneous expression with variable intensity in ductal structures. CD175, consistently positive in tumor cells, was identified as a potential complementary biomarker to CA19-9, which was co-detected with HECA-452 for CD15s.
Tags: anti-human CA19-9 1116-NS-19-9; anti-human CA19-9 1116-NS-19-9 mAb
Tumor‐Associated Carbohydrate Antigen 19–9 (CA 19–9), a Promising Target for Antibody‐Based Detection, Diagnosis, and Immunotherapy of Cancer
Nakisa, M., et al. ChemMedChem. 2024 Nov 7;e202400491. doi: 10.1002/cmdc.202400491. PMID: 39482752
The 1116-NS-19-9 monoclonal antibody identified CA19-9 in 1979, with a constructed scFv (RA9-23) showing stronger binding to WiDr and Capan-2 cell lines than the native antibody. Increased CA19-9 expression promoted tumor metastasis via E-selectin binding, and in mice, it caused severe pancreatitis through EGFR signaling hyperactivation.
Tags: anti-human CA19-9 1116-NS-19-9 antibody in vivo; anti-human CA19-9 1116-NS-19-9 in animal model
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Duffy, M. J., et al. World J Gastrointest Surg. 2020 Dec 27;12(12):468-481. doi: 10.4240/wjgs.v12.i12.468. PMID: 33352866
CA19-9, first identified in 1979 by the 1116-NS-19-9 antibody in the SW1116 colorectal carcinoma cell line, is a sialylated Lewis^a^ antigen associated with pancreatic ductal adenocarcinoma (PDAC). Its utility spans serum, saliva, pancreatic cysts, and immunohistochemical applications, reflecting its role as a key tumor marker in PDAC.
Tags: anti-human CA19-9 1116-NS-19-9 mAb in animal model; anti-human CA19-9 1116-NS-19-9 in cancer research
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
Ballehaninna, U. K., et al. J Gastrointest Oncol. 2012 Jun 1;3(2):105-119. doi: 10.3978/j.issn.2078-6891.2012.024. PMID: 22811875
CA19-9, identified by the 1116-NS-19-9 antibody in the SW1116 colorectal cancer cell line, is a key tumor marker for pancreatic cancer. A comprehensive review (1979–2010) evaluated its role in diagnosis, prognosis, and management, highlighting its utility despite the exploration of additional markers from serum, pancreatic tissue, and other fluids.
Tags: anti-human CA19-9 1116-NS-19-9 mAb in cancer research; anti-human CA19-9 (1116-NS-19-9) in vivo antibody
CA 19-9 and Pancreatic Cancer
Ballehaninna, U. K., et al. Gastroenterol Res Pract. 2013;2013:710836. doi: 10.1155/2013/710836. PMID: 23592950
CA19-9, a sialylated Lewis^a^ antigen identified by the 1116-NS-19-9 antibody in the SW1116 colorectal carcinoma cell line in 1979, is a component of glycoproteins and mucins. Its concentration, measured by ELISA, aids in detecting pancreatic cancer early, potentially improving prognosis through curative resection.
Tags: anti-CA19-9 clone 1116-NS-19-9; clone 1116-NS-19-9 of anti-human CA19-9 mAb
For more references about anti-human CA19-9 antibody (1116-NS-19-9), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf